ArticleThe Prostate2026
Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer.
Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFor patients with unfavorable intermediate or high risk localized prostate cancer receiving definitive radiotherapy, androgen deprivation therapy reduces recurrence and improves survival but is underutilized due to toxicity concerns. Patients who forgo initial ADT may later require salvage ADT. Robust real world risk estimates can guide counseling. PATIENTS AND
methodsWe conducted a retrospective cohort study using SEER-Medicare. Men aged 66 years diagnosed from 2010 to 2021 and treated with external beam radiotherapy were included. Exposure was concurrent ADT with radiotherapy versus radiotherapy alone. Salvage ADT was defined as initiation after the initial treatment period. We estimated cumulative incidence of salvage ADT accounting for death as a competing risk and used Fine-Gray models to obtain adjusted sub-distribution hazard ratios, controlling for demographics, tumor characteristics, and facility factors.
resultsAmong 5,092 patients with unfavorable intermediate-risk disease, 61.17% received concurrent ADT with definitive RT. Among 6,970 patients with high-risk disease, 89.60% received concurrent ADT with definitive RT. At 5 years, the adjusted cumulative incidence of salvage ADT was 3.53% (RT with ADT) versus 6.07% (RT alone) for unfavorable intermediate-risk, and 5.92% vs 19.17% for high-risk patients. On multivariable analysis, concurrent ADT with definitive RT was associated with a lower risk of salvage ADT in both the unfavorable intermediate-risk group (SHR, 0.56; 95% CI,A 0.45-0.70; p < 0.01) and the high-risk group (SHR, 0.26; 95% CI, 0.21-0.31; p < 0.01). Higher PSA was also associated with increased risk for salvage ADT for both risk groups, and higher Gleason score was also associated with increased salvage ADT in high-risk patients.
conclusionsOmission of initial ADT during RT is associated with an increased risk of salvage ADT in unfavorable intermediate-risk and high-risk prostate cancer. These real-world, population-based estimates help inform patient counseling and facilitate personalized treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.